These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 10530953)

  • 1. Synthesis and evaluation of homofarnesoyl-substituted CAAX-peptidomimetics as farnesyltransferase inhibitors and antiproliferative agents.
    Schlitzer M; Sattler I; Dahse HM
    Bioorg Med Chem; 1999 Sep; 7(9):2037-45. PubMed ID: 10530953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-thiol farnesyltransferase inhibitors: FTase-inhibition and cellular activity of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
    Mitsch A; Bergemann S; Gust R; Sattler I; Schlitzer M
    Arch Pharm (Weinheim); 2003 Jul; 336(4-5):242-50. PubMed ID: 12916059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [CAAX peptidomimetics: their farnesyltransferase inhibition activity and antitumor effect].
    Ohkanda J
    Seikagaku; 2002 Jan; 74(1):46-50. PubMed ID: 11889772
    [No Abstract]   [Full Text] [Related]  

  • 4. Non-thiol farnesyltransferase inhibitors: structure-activity relationships of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
    Schlitzer M; Böhm M; Sattler I
    Bioorg Med Chem; 2002 Mar; 10(3):615-20. PubMed ID: 11814849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-thiol farnesyltransferase inhibitors: the concept of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
    Schlitzer M; Sattler I
    Eur J Med Chem; 2000; 35(7-8):721-6. PubMed ID: 10960188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, molecular modeling, and structure-activity relationship of benzophenone-based CAAX-peptidomimetic farnesyltransferase inhibitors.
    Sakowski J; Böhm M; Sattler I; Dahse HM; Schlitzer M
    J Med Chem; 2001 Aug; 44(18):2886-99. PubMed ID: 11520197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different amino acid replacements in CAAX-tetrapeptide based peptidomimetic farnesyltransferase inhibitors.
    Schlitzer M; Sattler I; Dahse HM
    Arch Pharm (Weinheim); 1999 Apr; 332(4):124-32. PubMed ID: 10327885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and early structure-activity relationship of farnesyltransferase inhibitors which mimic both the peptidic and the prenylic substrate.
    Schlitzer M; Böhm M; Sattler I; Dahse HM
    Bioorg Med Chem; 2000 Aug; 8(8):1991-2006. PubMed ID: 11003144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probing the hydrophobic pocket of farnesyltransferase: aromatic substitution of CAAX peptidomimetics leads to highly potent inhibitors.
    Qian Y; Marugan JJ; Fossum RD; Vogt A; Sebti SM; Hamilton AD
    Bioorg Med Chem; 1999 Dec; 7(12):3011-24. PubMed ID: 10658608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure based design of benzophenone-based non-thiol farnesyltransferase inhibitors.
    Schlitzer M
    Curr Pharm Des; 2002; 8(19):1713-22. PubMed ID: 12171543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-thiol farnesyltransferase inhibitors: N-(4-tolylacetylamino-3-benzoylphenyl)-3-arylfurylacrylic acid amides.
    Mitsch A; Wissner P; Silber K; Haebel P; Sattler I; Klebe G; Schlitzer M
    Bioorg Med Chem; 2004 Sep; 12(17):4585-600. PubMed ID: 15358286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-methyl-1,2,4-triazol-3-yl heterocycle as an alternative to the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA.
    Angibaud P; Saha AK; Bourdrez X; End DW; Freyne E; Lezouret P; Mannens G; Mevellec L; Meyer C; Pilatte I; Poncelet V; Roux B; Smets G; Van Dun J; Venet M; Wouters W
    Bioorg Med Chem Lett; 2003 Dec; 13(24):4361-4. PubMed ID: 14643326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of 4-[(3-methyl-3H-imidazol-4-yl)-(2-phenylethynyl-benzyloxy)-methyl]-benzonitrile as novel farnesyltransferase inhibitor.
    Lin NH; Wang L; Cohen J; Gu WZ; Frost D; Zhang H; Rosenberg S; Sham H
    Bioorg Med Chem Lett; 2003 Nov; 13(21):3821-5. PubMed ID: 14552788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors.
    Lombardo LJ; Camuso A; Clark J; Fager K; Gullo-Brown J; Hunt JT; Inigo I; Kan D; Koplowitz B; Lee F; McGlinchey K; Qian L; Ricca C; Rovnyak G; Traeger S; Tokarski J; Williams DK; Wu LI; Zhao Y; Manne V; Bhide RS
    Bioorg Med Chem Lett; 2005 Apr; 15(7):1895-9. PubMed ID: 15780629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and evaluation of hydroxyproline-derived isoprenyltransferase inhibitors.
    O'Connell CE; Ackermann K; Rowell CA; Garcia AM; Lewis MD; Schwartz CE
    Bioorg Med Chem Lett; 1999 Jul; 9(14):2095-100. PubMed ID: 10450988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-peptidic, non-prenylic bisubstrate farnesyltransferase inhibitors. Part 3: structural requirements of the central moiety for farnesyltransferase inhibitory activity.
    Schlitzer M; Böhm M; Sattler I
    Bioorg Med Chem; 2000 Oct; 8(10):2399-406. PubMed ID: 11058034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-thiol farnesyltransferase inhibitors: utilization of the far aryl binding site by 5-cinnamoylaminobenzophenones.
    Mitsch A; Wissner P; Böhm M; Silber K; Klebe G; Sattler I; Schlitzer M
    Arch Pharm (Weinheim); 2004 Sep; 337(9):493-501. PubMed ID: 15362122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-thiol farnesyltransferase inhibitors: evaluation of different AA(X)-peptidomimetic substructures in combination with arylic cysteine replacements.
    Sakowski J; Böhm M; Sattler I; Schlitzer M
    Arch Pharm (Weinheim); 2002 Apr; 335(4):135-42. PubMed ID: 12112033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inhibitors of farnesyltransferase: a new approach for development of potential cancer drugs].
    Schlitzer M
    Pharm Unserer Zeit; 1998 Nov; 27(6):278-88. PubMed ID: 9894422
    [No Abstract]   [Full Text] [Related]  

  • 20. Pyridone-containing farnesyltransferase inhibitors: synthesis and biological evaluation.
    Hasvold LA; Wang W; Gwaltney SL; Rockway TW; Nelson LT; Mantei RA; Fakhoury SA; Sullivan GM; Li Q; Lin NH; Wang L; Zhang H; Cohen J; Gu WZ; Marsh K; Bauch J; Rosenberg S; Sham HL
    Bioorg Med Chem Lett; 2003 Nov; 13(22):4001-5. PubMed ID: 14592494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.